# TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC

> **NCT05250843** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Third Affiliated Hospital, Sun Yat-Sen University** · enrollment: 90 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **PROCEDURE:** TACE/HAIC
- **DRUG:** Lenvatinib
- **DRUG:** Sintilimab
- **PROCEDURE:** liver resection

## Key facts

- **NCT ID:** NCT05250843
- **Lead sponsor:** Third Affiliated Hospital, Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-30
- **Primary completion:** 2023-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2023-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05250843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05250843, "TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05250843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*